Alice Kaneditorial@labpulse.comSequencingSequencing seeks to stay ahead of new COVID-19 surgesSequencing has been an essential tool for the development of strategies and therapeutics in the fight against COVID-19, and sequencing-based rapid and high-throughput diagnostics for COVID-19 are in development. Sequencing technology suppliers are collaborating with researchers to develop sequencing-based diagnostic tools. For example, several groups are using Illumina's next-generation sequencing (NGS) technology to develop ultrahigh-throughput COVID-19 diagnostic testing.June 7, 2020PCRVendors struggle to supply RNA extraction kits due to COVID-19SARS-CoV-2, the coronavirus responsible for the COVID-19 illness, encodes its genome in a single-stranded RNA. In vitro diagnostics of COVID-19 are done by quantitative PCR (qPCR), but first RNA must be extracted from a patient sample and reverse transcribed.May 10, 2020Page 1 of 1Top StoriesCancerInvivoscribe, Complete Genomics partner to develop NGS tests for cancer research, detectionUnder the terms of the deal, Invivoscribe will be responsible for the development of biomarker tests, including test controls and associated bioinformatics software. The tests will run on Complete Genomics' NGS platforms.Regulatory ApprovalSeegene obtains IVDR certification for 30 diagnostic assaysPolicy and RegulationAdvocacy groups in letter urge FDA to develop regulations for lab-developed testsCollaborationNucleai, Adlai Nortye collaborate on biomarkers for clinical trialsSponsor ContentVisit our Molecular Diagnostics Community
